Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

European Journal of Cancer

Volumn 47, Issue 17, 2011, Pages 2592-2602

  Tomita, Yoshihiko ^a   Uemura, Hirotsugu ^b   Fujimoto, Hiroyuki ^c   Kanayama, Hiro Omi ^d   Shinohara, Nobuo ^e   Nakazawa, Hayakazu ^f   Imai, Keiji ^g   Umeyama, Yoshiko ^g   Ozono, Seiichiro ^h   Naito, Seiji ⁱ   Akaza, Hideyuki ^j,k  

^a YAMAGATA UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g PFIZER INC   (United States)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j UNIVERSITY OF TSUKUBA   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Axitinib; Biomarker; Proteinuria; Renal cell carcinoma; VEGFR 2

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; AXITINIB; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; JAPANESE; KIDNEY CARCINOMA; KIDNEY FUNCTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN URINE LEVEL; PROTEINURIA; SIDE EFFECT; STOMATITIS; SUBARACHNOID HEMORRHAGE; THORAX PAIN; THROMBOCYTOPENIA; THYROTOXICOSIS; TREATMENT RESPONSE; VOMITING; WEIGHT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80755140681     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.07.014     Document Type: Article

References (35)

1. K. Gupta, J.D. Miller, and J.Z. Li Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review Cancer Treat Rev 34 2008 193 205
2. B. Escudier, and V. Kataja Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 81 82
3. J.S. Lam, J.T. Leppert, A.S. Belldegrun, and R.A. Figlin Novel approaches in the therapy of metastatic renal cell carcinoma World J Urol 23 2005 202 212 (Pubitemid 41136043)
4. S. Oudard, D. George, J. Medioni, and R. Motzer Treatment options in renal cell carcinoma: past, present and future Ann Oncol 18 Suppl. 10 2007 25 31
5. S. Naito, N. Yamamoto, and T. Takayama Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients Eur Urol 57 2010 317 325
6. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.
7. J.A. Garcia, and B.I. Rini Recent progress in the management of advanced renal cell carcinoma CA Cancer J Clin 57 2007 112 125 (Pubitemid 46535711)
8. L.J. Costa, and H.A. Drabkin Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies Oncologist 12 2007 1404 1415
9. D.Y. Heng, and R.M. Bukowski Anti-angiogenic targets in the treatment of advanced renal cell carcinoma Curr Cancer Drug Targets 8 2008 676 682
10. W.K. Rathmell, and S. Chen VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment Expert Rev Anticancer Ther 8 2008 63 73
11. D.D. Hu-Lowe, H.Y. Zou, and M.L. Grazzini Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
12. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
13. E.E. Cohen, L.S. Rosen, and E.E. Vokes Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708 4713
14. J. Fruehauf, J. Lutzky, and D. McDermott Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study J Clin Oncol 26 Suppl. 15 2008 9006 [abstract]
15. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
16. J.H. Schiller, T. Larson, and S.H. Ou Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 2009 3836 3841
17. H.S. Rugo, A. Stopeck, and A.A. Joy A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) J Clin Oncol 25 Suppl. 18 2007 1003 [abstract]
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181 (Pubitemid 36962641)
20. J.P. Spano, C. Chodkiewicz, and J. Maurel Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 2008 2101 2108
21. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
22. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
23. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
24. H. Uemura, N. Shinohara, and T. Yuasa A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety Jpn J Clin Oncol 40 2010 194 202
25. M.H. Hong, H.S. Kim, and C. Kim Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea Cancer Res Treat 41 2009 67 72
26. E. Hwang, H.J. Lee, C.K. Sul, and J.S. Lim Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience Korean J Urol 51 2010 450 455
27. C. Yoo, J.E. Kim, and J.L. Lee The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction Jpn J Clin Oncol 40 2010 980 985
28. H. Zhang, B. Dong, and J.J. Lu Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study BMC Cancer 9 2009 249
29. H. Izzedine, C. Massard, and J.P. Spano VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management Eur J Cancer 46 2010 439 448
30. B.I. Rini, I. Tamaskar, and P. Shaheen Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 99 2007 81 83
31. I. Tamaskar, R. Bukowski, and P. Elson Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib Ann Oncol 19 2008 265 268 (Pubitemid 351201706)
32. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs; 2011. doi:10.1007/s10637-011-9637-1.
33. P. Wolter, C. Stefan, and B. Decallonne The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation Br J Cancer 99 2008 448 454
34. H. Miyake, T. Kurahashi, and K. Yamanaka Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation Urol Oncol 28 2009 515 519
35. R.K. Jain, D.G. Duda, and C.G. Willett Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338